mitotane
Selected indexed studies
- A review of mitotane in the management of adrenocortical cancer. (Oncologist, 2024) [PMID:39037424]
- Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. (Lancet Diabetes Endocrinol, 2023) [PMID:37619579]
- Understanding mitotane mode of action. (J Physiol Pharmacol, 2017) [PMID:28456766]
_Worker-drafted node — pending editorial review._
Connections
mitotane is a side effect of
Sources
- A review of mitotane in the management of adrenocortical cancer. (2024) pubmed
- Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. (2023) pubmed
- Understanding mitotane mode of action. (2017) pubmed
- Mitotane for adrenocortical carcinoma treatment. (2005) pubmed
- New perspectives for mitotane treatment of adrenocortical carcinoma. (2020) pubmed
- Pharmacological profile and effects of mitotane in adrenocortical carcinoma. (2021) pubmed
- Mitotane (o,p'-DDD). (1980) pubmed
- The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging. (2021) pubmed
- Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma. (2022) pubmed
- Combination chemotherapy in advanced adrenocortical carcinoma. (2012) pubmed